-
CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment
•
China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG: 9960) to advance precision diagnosis and treatment in blood tumors. The partnership aims to enhance educational activities, promote the concept of precision detection and treatment, and improve the accessibility and standardization of genetic testing for…
-
Wanbangde Pharmaceutical to Acquire Consun Pharma Shares in RMB 2.2B Deal
•
China-based Wanbangde Pharmaceutical Group has entered into a non-legally binding letter of intent with Consun Pharmaceutical Group Ltd (HKG: 1681) to acquire 238,056,948 shares at RMB 9.17 (USD 1.36) per share, valuing the transaction at approximately RMB 2.2 billion (USD 325 million). About Consun PharmaceuticalConsun Pharma, listed on the Hong…
-
Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1
•
China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab has demonstrated sustained neutralizing activity against the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 subvariants. Study ResultsLive virus neutralization experiments conducted in the US showed that 14 days after dosing, the total plasma concentration of the combination…
-
CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease
•
China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY Biopharma Co., Ltd, securing global rights to the latter’s tetravalent bispecific antibody (BsAb) targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANG2) for intravitreal injection. Financial terms were not disclosed. Agreement DetailsThe deal encompasses…
-
HitGen and LoQus23 Therapeutics Partner on DNA Encoded Library for Neurodegeneration
•
China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging its DNA Encoded Library (DEL) technology to screen compounds for targets identified by LoQus23. The collaboration aims to develop small-molecule drugs targeting DNA mismatch repair (MMR) to slow neurodegeneration in diseases like Huntington’s and myotonic…
-
Roche Diagnostics and Topgen Biopharm Launch Innovation Center in Chongqing
•
Swiss diagnostics giant Roche Diagnostics and China-based Topgen Biopharm announced the establishment of a strategic partnership on July 24, with the inauguration of the “Roche Diagnostics-Topgen Innovation Center of Excellence” in Chongqing. Center OverviewThe innovation center comprises several key facilities:
-
Hybio Pharmaceutical Signs Tech Transfer Deal with China’s CDC for COVID-19 Vaccine Peptide Sequences
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that it has signed a technology transfer agreement with the National Institute for Viral Disease Control and Prevention, China’s CDC. The deal grants Hybio licensed use of technical secrets related to peptide sequences for vaccine development. Agreement DetailsHybio will pay an upfront…
-
Yunnan Baiyao and Huawei Partner on AI-Driven Drug Development
•
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a Kunming-based pharmaceutical firm, has entered into a three-year partnership with Huawei Technologies Co., Ltd to explore the application of artificial intelligence (AI) in drug development. The collaboration will focus on macro and small molecule drug design, related diseases, and database development. Partnership…
-
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration (NMPA) has accepted a market filing from its non-wholly owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd for a combination therapy of fulvestrant and piroxetine in advanced breast cancer. This marks Xuanzhu Bio’s first filing for an…
-
Sichuan Kelun Pharmaceutical and Merck Sharp & Dohme Corp. Ink Second ADC Licensing Deal
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme Corp. (MSD) has entered into a second licensing agreement, securing global development, manufacturing, and commercialization rights to an undisclosed investigational antibody drug conjugate (ADC) from Kelun’s pipeline. The deal includes an upfront payment of USD…
-
SinoPharm CNBG’s F61 Monoclonal Antibody Receives NMPA Clinical Trial Approval
•
SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus monoclonal antibody (mAb), has received clinical trial approval from the National Medical Products Administration (NMPA). Development and ResearchF61 was co-developed by Yang Xiaoming’s team with CNBG and Liang Mifang’s team from the Chinese Center for…
-
Legend Biotech Plans USD 250M Secondary Offering to Fund CAR-T Therapy Development
•
China-based Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T cell therapy, announced plans to raise USD 250 million through a secondary public offering of American Depositary Shares (ADSs). Each ADS represents two ordinary shares. The underwriters have a 30-day option to purchase an additional USD…
-
AbbVie’s Allergan Aesthetics CoolAdvantage Applicator Wins NMPA Approval
•
US-based AbbVie’s Allergan Aesthetics announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its CoolAdvantage applicator series, alongside its official market launch in China. Technology and FeaturesCoolSculpting utilizes a non-surgical process called cryolipolysis to target and reduce subcutaneous fat by cooling fat cells to…
-
Henlius Biotech’s Hanquyou Approved in Australia for HER2-Positive Cancers
•
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received marketing approval from Australia’s Therapeutic Goods Administration (TGA) for its Hanquyou (trastuzumab injection, EU trade name: Zercepac). The drug will be marketed under the trade names Tuzucip and Trastucip to treat HER2-positive early breast cancer, HER2-positive locally advanced breast…
-
Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study
•
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct an open-label, multi-center Phase Ib/II clinical study of its SHR-1802 combined with SHR-1316 for advanced solid tumors. Drug Profiles Global PD-L1 MarketGlobal PD-L1 products include AstraZeneca’s Tecentriq…
-
Betta Pharmaceuticals Enrolls First Patient in BPI-442096 Phase I Study for Solid Tumors
•
China-based Betta Pharmaceuticals (SHE: 300558) announced that the first subject has been enrolled in a Phase I clinical study of BPI-442096 for advanced solid tumors. The multi-center trial, which includes dosage escalation and expansion phases, will assess the safety, tolerability, and preliminary efficacy of BPI-442096, and determine the maximum tolerated…
-
Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study
•
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase Ib/II clinical study of SHR-A1811, a HER2-targeted antibody drug conjugate (ADC), combined with SHR-1316 or pyrotinib for advanced non-small cell lung cancer (NSCLC) with HER2…
-
Ascentage Pharma Launches Olverembatinib Named Patient Program with Tanner Pharma
•
China-based Ascentage Pharma (HKG: 6855) announced the launch of a Named Patient Program (NPP) for its drug olverembatinib in partnership with US-based Tanner Pharma Group. The program aims to provide access to the drug in over 100 countries and regions where it is not yet commercially available. Drug ProfileOlverembatinib is…
-
Sirnaomics’ STP705 Receives Approval for Liver Cancer Trial in Taiwan
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from the Ministry of Health and Welfare of Taiwan to conduct a Phase I clinical study of its therapeutic candidate STP705 for advanced liver cancer. Drug ProfileSTP705 is a siRNA (small interfering RNA) therapeutic that leverages…
-
GenFleet Therapeutics’ GFH018 Receives CTA Approval for Two Clinical Trials in China
•
Shanghai-based biotech company GenFleet Therapeutics announced that two clinical trial applications (CTAs) for its drug candidate GFH018 have been approved in China. GFH018 is a small molecule designed to specifically target and inhibit TGF-ß R1. Clinical Trial Details SignificanceThe TGF-ß signaling pathway is a key target for multiple solid tumors.…
